Gritstone bio Inc (GRTS) 시세

BANKRUPTCY DUMPING

bankrupt

https://stockcharts.com/h-sc/ui RSI is at 22

Funny part 16 million buys to 12 million sells 2 million neutral.

UNBELIEVABLE DUMPING

Including neoantigens for recognition by CD4+ T-cells greatly improved the effectiveness, while tumour-unrelated CD4+ T-cell antigens did not https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(24)00077-8

Still the only company I'm aware of that is able to induce such a rapid, robust and consistent large number of CD8+ T-cells.



But having a strong CD8+ T-cell response is useless without the right selection https://www.science.org/doi/10.1126/scitranslmed.aax7918

EDGE does not specifically model immunogenicity but performs reasonably well at predicting immunogenic peptides (immunogenicity is >50% of mutations per patient generate a detectable CD8+ T-cell response).

CD4+ T-cell responses are important as well (but prediction is a lot harder) https://www.nature.com/articles/s41586-019-1671-8

Also, what setting it is given is equally important. They (vaccines in general) likely offer a greater benefit to the patient if administered in earlier clinical settings, such as the adjuvant setting, for a number of reasons.

GRTS new 52 lo

And then the offering....classic bs

GRTS—(-40%/AH)—reports purportedly-positive interim phase-2 data:

https://www.globenewswire.com/news-release/2024/04/01/2855416/0/en/Gritstone-bio-Announces-Positive-Preliminary-Progression-free-Survival-and-Long-term-Circulating-Tumor-DNA-ctDNA-Data-from-Phase-2-Portion-of-Ongoing-Phase-2-3-Study-of-its-Persona.html Gritstone bio…today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC).

Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Emphasis added.

The results could be difficult to interpret as Gritstone is primarily evaluating ctDNA, an endpoint that doesn't have the full backing from any regulator that I know of. Gritstone could also report other data, but the company argues that radiographic endpoints aren't as good as ctDNA, which means that the endpoints might not match up.

Yep, looking past $3 now…let’s ride!!!😎🍻🍻✌️

grts breaking 2.75 trigger

GRTS...NEXT STOP 2.75

GRTS MONSTER CANCER PLAY

GRTS WHAT A MONSTER...LETS SEE 2.46 NEXT

GRTS....READY FOR 2.32

That’s next…

GRTS...I THINK THEY CURED CANCER

GRTS READY FOR 2.37

Merry Christmas $$$

GRTS under $2

Wow, finally some company. LOL!!! Oncology side is even stronger. Barda $$$ was great though. LFG!!!

Gritstone Bio shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7. >>>>> GRTS

I wonder how many people know that this is a cornovavirus stock company… hmmm

Sounds like you're keeping a close eye on this one. Hoping for the best!

This is just the appetizer. Shorties going to get roasted once float locks up. Lots of shares sold at these levels. Longs or quick flippers should be rewarded soon

GRTS..BREAKING NICELY

Merry Christmas $$$

They are trying for that cup and handle. Let's goo

Getting up for the next leg. Get in or get left behind.

All IMO of course. Trading well, should be trading much better with a $400 mil grant. I suspect some manipulation to take all the shares they can get.

GRTS ANOTHER BIO READY

Share price holding in AH . Let's see how she runs tomorrow.

Maybe government grants don't count in totaling yearly revenues ! > $$$$$

WE ARE LIKE

underpaid news reporters

https://finviz.com/quote.ashx?t=GRTS&p=d

Barely anyone is selling, and the shorts disappeared…..



Wow, looks good for tomorrow


Have a great night

Latest News

UPDATE 1-Gritstone bio wins $433
million US contract for COVID vaccine study
Sep 27, 2023 at 4:48 p.m. ET
(Adds share price and study details in paragraphs 3-5)
Sept 27 (Reuters) - Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.
The contract is a part of "Project NextGen," an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.
Gritstone's shares rose 36.1% to $1.61 after the bell.
The study will compare the efficacy, safety and immunogenicity of Gritstone's COVID-19 vaccine candidate with an approved vaccine.
Gritstone plans to initiate the mid-stage study in the first quarter of next year.
The contract was awarded by the Biomedical Advanced Research and Development Authority, a U.S. federal agency that funds disease-fighting technology.

WOOHOOOOOO WOOHOOOOOO

Looks like that’s going to change

Horrible Revenues > According to MarketWatch, GRTS annual revenue averages $11,000. per employee.

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.

We’ll look shorts are in

Lucky I bought after market, let’s see tomorrow what happens


Have a good night

WOOHOOOOOO

Looking great

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
-- 10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 --

-- Contract is part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 --

EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets to protect against COVID-19. The agreement, which is valued at up to $433 million, was awarded as part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19.

Under the contract, Gritstone bio will conduct a 10,000 participant, randomized Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of the Gritstone next-generation COVID-19 vaccine candidate with an approved COVID-19 vaccine. Preparations for the study are underway, and execution of the study will be fully funded by BARDA. Gritstone will run the study in the United States in collaboration with the COVID-19 Prevention Network (CoVPN), a NIAID-supported network of clinical trial sites based at Fred Hutchinson Cancer Center with experience conducting large COVID-19 vaccine trials.

“We are honored to receive this award from BARDA to advance our next-generation samRNA vaccine against COVID-19 (the CORAL program), which provides strong validation of our innovative vaccine platform in infectious diseases. Not only does this contract supply the necessary resources to advance the development of CORAL, but it also signifies the trust and confidence the U.S. government has placed in our novel vaccine approach,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. “First-generation COVID-19 vaccines provided great utility during the height of the pandemic but are limited in breadth and durability of clinical protection. CORAL was designed to address these limitations by inducing durable neutralizing antibody and T cell-based immunity against current and future SARS-CoV-2 variants. Across multiple Phase 1 studies, our samRNA vaccine, which incorporates both Spike and other viral targets (Spike plus), has demonstrated induction of potent immune responses with potential to drive broad and durable clinical protection – this potential will now be tested in a randomized setting. We are excited about this opportunity to work alongside BARDA and look forward to initiating the Phase 2b study (CORAL-BARDA) in the first quarter of 2024. With CORAL moving into a randomized Phase 2 study alongside our personalized cancer vaccine program (GRANITE), Gritstone now sits at the precipice of unlocking the full potential of our novel vaccine platforms in both oncology and infectious diseases.”

This project has been funded with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00062.

About the CORAL Program
Gritstone’s CORAL program is applying Gritstone’s infectious disease approach for the prevention of COVID-19. The program aims to drive both B cell and T cell immunity using self-amplifying mRNA (samRNA) and novel immunogens containing Spike plus additional viral targets. To date, the CORAL program has comprised three Phase 1 trials evaluating multiple samRNA vaccine candidates across various patient populations and settings: CORAL-BOOST (healthy volunteers following primary series of currently approved COVID-19 vaccines); CORAL-CEPI (vaccine-naïve healthy and HIV+ subjects in South Africa); and CORAL-NIH (run by the National Institute of Allergy and Infectious Disease [NIAID] in previously vaccinated healthy volunteers). Results to date have demonstrated induction and persistence of high neutralizing antibody levels through at least 6 months as well as broad T cell responses. The CORAL program is supported by Biomedical Advanced Research and Development Authority (BARDA), NIAID, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation.

About Self-amplifying mRNA (samRNA)
Self-amplifying mRNA (samRNA) is rapidly emerging as a well-tolerated, scalable and widely-applicable platform technology which can be used to develop multiple vaccines simply by changing the sequence of the antigen (the target of the immune system) that is encoded in the vector RNA and delivered in a lipid nanoparticle. Like traditional mRNA vaccines, samRNA vaccines use the host cell’s translation system to convert mRNA to protein target antigens in order to stimulate immunity. Unlike traditional mRNA, samRNA creates multiple copies of the antigen RNA once in the cell, potentially leading to extended duration and magnitude of antigen expression. Gritstone designs novel immunogens, the vaccine regions encoding virus antigens, and includes both Spike antigen (similar to first-generation COVID-19 vaccines) and evolutionarily conserved, non-Spike antigens likely to drive T cell responses in its next-generation COVID-19 vaccines. Potential benefits of this samRNA “Spike plus” approach include (1) strong and durable induction of neutralizing antibodies to Spike, (2) broad and durable T cell immunity (CD4+ and CD8+) to multiple viral proteins, (3) potency at lower doses (dose sparing), and (4) refrigerator stability.

About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets.

500 million in funding nice

GRTS$

AACR PR https://www.globenewswire.com/news-release/2023/04/17/2647754/0/en/Gritstone-bio-Presents-Advances-in-Neoantigen-Prediction-and-Cancer-Vaccine-Immunogenicity-at-the-2023-AACR-Annual-Meeting.html

Nice...$$$$!!!????????